Manufacturing Chemist Manufacturing Chemist
  • Home
  • Ingredients
  • Analysis
  • Manufacturing
  • Finance
  • Events
  • Directory
  • Regulatory
  • Drug Delivery
  • Research & Development
  • Sustainability

Valeant Pharmaceuticals

www.valeant.com

2150 St. Elzéar Blvd West
Laval
Quebec
H7L 4A8
Canada

+1 905 286 3000

Activities

Manufacturing | Research & Development | Pharmaceutical

Related Companies

  • Romaco Holding GmbH
  • Titan Enterprises
  • Icrom SRL
  • Huber
  • Nanoform
  • GEA Pharma and Healthcare
  • Starlab
  • Adare Pharma Solutions
  • Beamex
  • Burkert Fluid Control Systems
  • Envair Technology
  • Biopharma Group
  • Asynt
  • PCI Pharma Services
  • Watson Marlow Fluid Technology Solutions
  • Labtex
  • Piramal Pharma Solutions
  • LB Bohle
  • Vetter Pharma International
  • Butterworth Laboratories

Related Content

Sobi enters into new distribution agreement with Valeant for Ammonul
Sobi enters into new distribution agreement with Valeant for Ammonul
A precision medicine approach to developing cancer vaccines
A precision medicine approach to developing cancer vaccines
Valeant Canada expands with $27.5m investment
Valeant Canada expands with $27.5m investment
Valeant Pharmaceuticals names Joseph Papa as Chairman and Chief Executive
Valeant Pharmaceuticals names Joseph Papa as Chairman and Chief Executive
Valeant Pharmaceuticals makes management change
Valeant Pharmaceuticals makes management change
J. Michael Pearson returns as CEO of Valeant following illness
J. Michael Pearson returns as CEO of Valeant following illness
Opinion: Politics, passion and patient power
Opinion: Politics, passion and patient power
Valeant Pharmaceuticals to acquire Synergetics USA
Valeant Pharmaceuticals to acquire Synergetics USA
Valeant Pharmaceuticals to buy Sprout Pharmaceuticals for US$1bn in cash
Valeant Pharmaceuticals to buy Sprout Pharmaceuticals for US$1bn in cash
Valeant to acquire Amoun Pharmaceutical
Valeant to acquire Amoun Pharmaceutical
Valeant increases offer for Salix to US$15.8bn in cash
Valeant increases offer for Salix to US$15.8bn in cash
Endo submits offer to purchase Salix Pharmaceuticals for about US$15.7bn
Endo submits offer to purchase Salix Pharmaceuticals for about US$15.7bn
Valeant to buy Salix Pharmaceuticals for US$14.5bn
Valeant to buy Salix Pharmaceuticals for US$14.5bn
Opinion: Still not getting it right
Opinion: Still not getting it right
Microbial contamination causes Valeant Pharmaceutical North America to recall Virazole
Microbial contamination causes Valeant Pharmaceutical North America to recall Virazole
  • Advertise Subscribe
  • Terms & Conditions
  • Privacy Policy
  • Contact us at info@hpcimedia.com
Twitter LinkedIn RSS newsfeed
© HPCi Media Limited | Registered in England No. 6716035 | VAT GB 939828072 | a Claverley Group company